Novozymes signs agreement for NgAgo

David Cyranoski, Nature News, 23 January 2017, http://www.nature.com/news/biotech-firm-backs-controversial-crispr-challenger-1.21343

NgAgo was initially reported as a DNA-guided, DNA-targeting enzyme similar to the CRISPR/Cas system. However, many scientists have questioned the validity of the initial study.  Despite these questions, Novozymes has signed an agreement with the Chinese university that developed NgAgo to explore its uses.  Novozymes spokesperson Dongyi Chen states that Novozymes has “tested the technology and seen indications that it might be useful, but it is very early in the development.”

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply